Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-597-5002
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees62
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Allakos (NASDAQ:ALLK) Frequently Asked Questions
What is Allakos' stock symbol?
Allakos trades on the NASDAQ under the ticker symbol "ALLK."
How were Allakos' earnings last quarter?
Allakos Inc (NASDAQ:ALLK) released its quarterly earnings data on Monday, August, 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. View Allakos' Earnings History.
When is Allakos' next earnings date?
What is the consensus analysts' recommendation for Allakos?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allakos.
What are Wall Street analysts saying about Allakos stock?
Here are some recent quotes from research analysts about Allakos stock:
- 1. According to Zacks Investment Research, "Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. " (8/16/2019)
- 2. William Blair analysts commented, "Wenzel has extensive experience conducting clinical trials in asthma patients, including as lead author in the Phase II trials of Dupixent (Wenzel et al., 2016) and co-author in the Phase III trials. For additional background on PRS-060 and FeNO biology , see our recent note, at ERS With Promising Clinical Profile." (8/9/2019)
Has Allakos been receiving favorable news coverage?
Media coverage about ALLK stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allakos earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Allakos.
Are investors shorting Allakos?
Allakos saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 7,930,000 shares, an increase of 13.3% from the August 30th total of 7,000,000 shares. Based on an average daily trading volume, of 687,700 shares, the short-interest ratio is presently 11.5 days. Currently, 35.5% of the shares of the company are sold short. View Allakos' Current Options Chain.
Who are some of Allakos' key competitors?
Some companies that are related to Allakos include Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Perrigo (PRGO), SAGE Therapeutics (SAGE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY) and Sarepta Therapeutics (SRPT).
What other stocks do shareholders of Allakos own?
Who are Allakos' key executives?
Allakos' management team includes the folowing people:
- Dr. Robert Alexander, Pres, CEO & Director (Age 49)
- Dr. Adam L. Tomasi, CFO, COO & Sec. (Age 49)
- Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 60)
- Dr. Ruby Casareno Ph.D., VP of Technical Operations
- Mr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 56)
When did Allakos IPO?
(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.
How do I buy shares of Allakos?
Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Allakos' stock price today?
One share of ALLK stock can currently be purchased for approximately $69.97.
How big of a company is Allakos?
Allakos has a market capitalization of $3.02 billion. The company earns $-43,540,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Allakos employs 62 workers across the globe.View Additional Information About Allakos.
What is Allakos' official website?
How can I contact Allakos?
Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]
MarketBeat Community Rating for Allakos (NASDAQ ALLK)
MarketBeat's community ratings are surveys of what our community members think about Allakos and other stocks. Vote "Outperform" if you believe ALLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
